Melanotan II

Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH). Its primary mechanism of action involves acting as a non-selective agonist of melanocortin receptors (MCRs), specifically MC1R, MC3R, MC4R, and MC5R. The activation of these receptors leads to a variety of physiological effects:

• Melanogenesis (Tanning): Activation of the MC1R, primarily on melanocytes, stimulates the production and dispersion of melanin, leading to skin darkening or tanning. This is the most well-known effect.
• Sexual Function: Activation of MC3R and MC4R in the central nervous system is implicated in its effects on erectile function and libido. These receptors play a role in central regulation of sexual behavior.
• Appetite and Energy Homeostasis: Activation of MC3R and MC4R in the hypothalamus also influences appetite suppression and energy expenditure. Research has shown that melanocortin signaling is crucial for regulating body weight.
• Neuroprotection and Anti-inflammation: Some research suggests that melanocortin receptor agonists may have neuroprotective and anti-inflammatory properties, though these areas are less extensively studied for Melanotan II specifically.

Its broad activity across multiple melanocortin receptor subtypes contributes to its diverse observed effects in research models.

Melanotan II has been the subject of **preclinical research** and limited human investigations, primarily exploring its potential applications in dermatological and sexual health contexts. Key areas of research focus include:

• Photoprotection and Skin Pigmentation: Extensive research aims to understand its efficacy in inducing skin tanning and potentially protecting against UV-induced skin damage and skin cancer, especially in individuals prone to sunburn.
• Sexual Dysfunction: Investigations into its ability to treat erectile dysfunction and enhance libido in both men and women, based on its central melanocortin receptor activation.
• Weight Management: Early studies have explored its effects on appetite suppression and weight loss due to its interaction with hypothalamic melanocortin pathways.
• Pharmacokinetics and Safety Profile: Fundamental research characterizes its absorption, distribution, metabolism, and excretion, as well as its acute and chronic safety in animal models.

It is important to note that while some studies have progressed to human trials, Melanotan II remains an **investigational research chemical** and is not approved by regulatory bodies for any therapeutic use due to concerns about safety and efficacy.

While Melanotan II has been used off-label by individuals, formal, large-scale **clinical trial findings** establishing its safety and efficacy for therapeutic use are limited, and it remains largely an investigational compound. Some early-phase studies and case reports have noted:

• Tanning Efficacy: Studies have shown that Melanotan II can induce significant skin darkening even with minimal UV exposure, particularly in individuals with lighter skin types. This effect is consistent across various limited human trials.
• Erectile Dysfunction: Early clinical trials in men with erectile dysfunction reported positive effects on erection quality and duration. Its efficacy for this purpose appears to be mediated centrally.
• Appetite Suppression: Some human studies indicated that Melanotan II can lead to reduced food intake and weight loss, though this was often accompanied by undesirable side effects.
• Adverse Effects: Common reported side effects in human studies and anecdotal reports include nausea, vomiting, facial flushing, increased libido, spontaneous erections, and darkening of moles and freckles. More serious adverse events, though rare, have been reported in case studies (e.g., renal infarction).

It is crucial to emphasize that despite some observed effects in limited human trials, Melanotan II's overall risk-benefit profile has not been fully established for clinical use. It is **not an FDA-approved drug** and its use outside of controlled research settings is discouraged due to potential uncharacterized side effects and safety concerns.

For optimal stability and preservation of Melanotan II, observe the following recommendations:

• Storage: Store lyophilized powder at -20°C to -80°C (long-term) or 2°C to 8°C (short-term, for up to 2-4 weeks), away from light and moisture.
• Reconstitution: Reconstitute with sterile, deionized water or a suitable solvent as per specific experimental protocols. Avoid repeated freeze-thaw cycles.
• Manejo Handle under aseptic conditions to prevent contamination. Use appropriate personal protective equipment (PPE), including gloves and eye protection.
• Stability: Once reconstituted, solutions should be stored at 2°C to 8°C and used within a short period, typically 24-72 hours, depending on the solvent and concentration. Long-term storage of reconstituted solutions is not recommended.
• Disposal: Dispose of Melanotan II and any waste materials in accordance with local and institutional hazardous waste regulations.

Strict adherence to these guidelines will help maintain the integrity and purity of the compound for research applications.

For more detailed information on Melanotan II and its research applications, please refer to the following scientific literature and review articles:

• Hadley ME. Discovery of α-melanocyte stimulating hormone as a tanning peptide. J Dermatol Sci. 2006 Dec;44(3):189-98. PMID: 17029198 (General discovery of α-MSH)
• Wessells H, et al. Melanocortin receptor agonists in the treatment of sexual dysfunction. Pharmacol Rev. 2012 Mar;64(1):151-68. PMID: 22409748 (Review of melanocortin agonists for sexual dysfunction, including MT-II)
• MacKenzie DS, et al. Melanocortin receptors: beyond pigmentation. Trends Pharmacol Sci. 2004 Aug;25(8):417-25. PMID: 15289196 (Broader review of MCR functions)
• Lim J, et al. Melanocortin agonists and antagonists for the treatment of obesity. Nat Rev Endocrinol. 2018 Sep;14(9):527-542. PMID: 29099882 (Review on MCRs and obesity)
• Ahmadi S, et al. Melanotan II: a possible cause of renal infarction: review of the literature and case report. J Med Case Rep. 2020 Apr 12;14(1):58. PMID: 32284061 (Case report highlighting a serious adverse effect)
• PubChem Compound Summary: Melanotan II (CID 92432)

*(Note: References are primarily focused on preclinical and mechanistic studies, reflecting Melanotan II's status as a research compound.)*

This product, Melanotan II, is sold exclusively for **research and development purposes**. It is classified as a research chemical and is **not a drug, food, or cosmetic**. It has not been evaluated or approved by the FDA or any other regulatory authority for safety, efficacy, or any other use in humans or animals. By purchasing this product, the user acknowledges and agrees to comply with all applicable local, national, and international laws and regulations regarding the handling, storage, and use of research compounds. Any use of this product for purposes other than legitimate scientific research is strictly prohibited and may lead to severe legal and health consequences.